<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092048</url>
  </required_header>
  <id_info>
    <org_study_id>CML0922</org_study_id>
    <nct_id>NCT05092048</nct_id>
  </id_info>
  <brief_title>A Study for PRO of CML in Real Word</brief_title>
  <acronym>Case-Only</acronym>
  <official_title>Validation Value of the Questionnaire to Assess Health-related Quality of Life in Patients With CML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>xuna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients&#xD;
      and careful monitoring of treatment responses by their physicians. Patient Reported&#xD;
      Outcomes(PRO) assessment is important to facilitate decisions in the current treatment&#xD;
      landscape of CML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Above 18 years of age.&#xD;
&#xD;
        2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL&#xD;
           positive chronic myeloid leukemia (CML).&#xD;
&#xD;
        3. Written informed consent.&#xD;
&#xD;
        4. Patients enrolled in investigational drug-trials or other type of clinical trials are&#xD;
           also eligible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Assess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia</measure>
    <time_frame>1 year</time_frame>
    <description>Health-related quality of life (HRQOL) assessment in the current treatment landscape of chronic myeloid leukemia</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>CML (Chronic Myelogenous Leukemia)</condition>
  <arm_group>
    <arm_group_label>CML patient</arm_group_label>
    <description>â‰¥18 years old CML patiente</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>PHQ-9 and GAD-7 questionnaire</description>
    <arm_group_label>CML patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Above 18 years of age. Patient with confirmed diagnosis of Philadelphia chromosome positive&#xD;
        and/or BCR-ABL positive chronic myeloid leukemia (CML).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>na xu, doctor</last_name>
    <phone>02062787883</phone>
    <email>292347668@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Nanfang Hospital, Southern Medical University,</name>
      <address>
        <city>Guanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Department of Hematology Nanfang Hospital Southern M University</last_name>
      <phone>02062787883</phone>
      <email>292347668@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>xuna</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

